Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors

Bibliographic Data

ID23235136
AuthorsMasato Ogawa (0000-0002-4165-0267, corresponding author), Maryam Fouladi (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Fred Laningham (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Jianrong Wu (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Melinda A O'Shaughnessy (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Kristen Molina (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Alberto Broniscer (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Sheri L Spunt (0000-0002-1669-2676, From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Inga Luckett (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Clinton F Stewart (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Peter J Houghton (0000-0002-2400-8184, From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Richard J Gilbertson (From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN), Wayne L Furman (0000-0001-7352-3556, From the Departments of Oncology, Radiological Sciences, Biostatistics, Developmental Neurobiology, Pharmaceutical Sciences, Pathology, and Molecular Pharmacology, St Jude Children's Research Hospital; and Department of Pediatrics, The University of Tennessee School of Medicine, Memphis, TN)
Year2007
Volume25
Issue30
Pages4806-4812
Publication date2007-10-20
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueJournal of Clinical Oncology (JOURNAL)
Journal identifiersISSN: 0732-183X • E-ISSN: 1527-7755
PublisherAmerican Society of Clinical Oncology (ASCO) (PUBLISHER)
DOI10.1200/jco.2007.11.4017
PMID17947729
OpenAlexW17947729
LanguageEN
Citations received3
References cited37

Continuous, orally administered everolimus is well tolerated in children with recurrent or refractory solid tumors and demonstrates similar pharmacokinetic properties to those observed in adults. Everolimus significantly inhibits the mTOR signaling pathway in children at the MTD. The recommended phase II dose in children with solid tumors is 5 mg/m2.

Democracy · Political science · Politics · Sociology · World War II · Asian American and Pacific Histories · Gender Studies · History · Law

Tools

Open DOISci-Hub